Theravance Biopharma, Inc.
TBPH
$17.06
-$0.01-0.03%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 17.13% | -61.43% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 17.13% | -61.43% | |||
| Cost of Revenue | -19.16% | -20.80% | |||
| Gross Profit | 34.95% | -69.19% | |||
| SG&A Expenses | -20.00% | -4.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.79% | -9.01% | |||
| Operating Income | 131.50% | -129.23% | |||
| Income Before Tax | 25.95% | -108.85% | |||
| Income Tax Expenses | 172.02% | -112.76% | |||
| Earnings from Continuing Operations | -19.56% | -108.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.56% | -108.08% | |||
| EBIT | 131.50% | -129.23% | |||
| EBITDA | 140.41% | -126.80% | |||
| EPS Basic | -18.71% | -108.02% | |||
| Normalized Basic EPS | 286.42% | 94.59% | |||
| EPS Diluted | -18.71% | -108.33% | |||
| Normalized Diluted EPS | 286.42% | 94.36% | |||
| Average Basic Shares Outstanding | 0.76% | 0.81% | |||
| Average Diluted Shares Outstanding | 0.76% | -3.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||